Platelet Aggregation After Thrombolytic Therapy

Griguer, P.; Mireille-Brochier; Leroy, J.; Leclerc, Marie-Hélène; Antoine, G.; Bertrand, H.; Chalons, F.
February 1980
Angiology;Feb1980, Vol. 31 Issue 2, p91
Academic Journal
Using Urokinase (UK) in the management of acute myoeardial infarction (AMI) and pulmonary embolism (PE), we observed an unexpected side effect of thrombolytic therapy the enhancement of platelet aggregation. We have studied this platelet hyperaggregation process in 244 subjects, 70 normal blood donors, and 174 patients with AMI or PB. To do this we used a simplified turbidimetric method, in vivo and in vitro. The patients were divided into five groups: Group 1: 70 normal donors; Group 2: 10 AMI patients treated with Heparin (HEP); Group 3: 12 AMI patients and 14 PE patients treated with HEP and UK; Group 4: 30 AMI patients treated with HEP and dipyridamole (Dip); Group 5: 108 patients, 44 with AMI and 64 with PE, treated with HEP, UK, and Dip. We observed platelet hyperaggregation in AMI and PE patients, which was already present before treatment and more frequent in PE than in AMI. This hyper aggregation is significantly enhanced in UK group (Group 3). It could be inhibited with Dip (Group 5).


Related Articles

  • Utilization of alteplase in trauma victim with an open abdomen. Martin, Sharolyn L.; Tellez, M. Geno // Journal of Emergencies, Trauma & Shock;Jul2011, Vol. 4 Issue 3, p427 

    Trauma victims with multisystem injuries are at risk for the development of deep vein thrombosis and pulmonary embolus (PE). The use of thrombolytic therapy remains very controversial and not well-documented in both the postsurgical and trauma subset of patients. Major trauma, surgery or head...

  • Angioplasty's margin of superiority over thrombolysis for acute MI may be less than thought.  // Modern Medicine;May96, Vol. 64 Issue 5, p32 

    Reports on the use of thrombolytic therapy as a primary therapeutic strategy for patients with myocardial infarction. Results of the study `Global Use of Strategies to Opn Occluded Arteries in Acute Coronary Syndromes'; Comparison of thrombolytic therapy with angioplasty.

  • The NHAAP: Making the most of thrombolytic therapy. Rodrigue, Roger B. // American Family Physician;3/1/1994, Vol. 49 Issue 4, p723 

    Editorial. Focuses on the use of thrombolytic therapy for acute myocardial infarction. Purpose of the US National Heart, Lung and Blood Institute's National Heart Attack Alert Program; Benefits of thrombolytic therapy.

  • Better management of MI is improving patient outcomes, registry data finds.  // Hospital Formulary;Feb95, Vol. 30 Issue 2, p79 

    Reports that management of myocardial infarction (MI) is changing for the better with a trend toward increased use of thrombolytic therapy and more frequent use of pharmacologic agents. Other treatments used; Decline in calcium channel blockers use.

  • Pharmacologic therapies after MI appear more cost effective than thrombolytics.  // Hospital Formulary;Feb95, Vol. 30 Issue 2, p80 

    Reports that the cost effectiveness of post-myocardial infarction (MI) pharmacologic therapies compares favorably with that of thrombolytic treatment of MI. Cost effectiveness analysis performed using relative risk reduction of agents and their cost; Aspirin as most cost effective therapy.

  • Prasugrel: A Review of its Use in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Duggan, Sean T.; Keating, Gillian M. // Drugs;Aug2009, Vol. 69 Issue 12, p1707 

    Summary: Prasugrel (Efient®) is a potent, selective and irreversible inhibitor of adenosine diphosphate (ADP)-mediated platelet aggregation that is indicated for the prevention of atherothrombotic events in patients with acute coronary syndromes (ACS) [comprising unstable angina...

  • COMMENTARY: Persistent right ventricular dysfunction increased risk for recurrent venous thromboembolism after acute pulmonary embolism. Douketis, James; Kaatz, Scott // ACP Journal Club;Mar/Apr2007, Vol. 146 Issue 2, p46 

    The article presents the authors' views about a study which states that persistent right ventricular dysfunction (RVD) increased risk for recurrent venous thromboembolism (VTE) after acute pulmonary embolism (PE). Although the findings of the study has been associated with increased short-term...

  • THROMBOLYSIS AS AN ALTERNATIVE TO PULMONARY EMBOLECTOMY. Porter, John M. // Vascular Surgery;Nov/Dec1977, Vol. 11 Issue 6, p373 

    Discusses the potential application of thrombolysis as an alternative to pulmonary embolectomy. Incidence and acute survival statistics of pulmonary embolism; Role of heparin in the treatment of pulmonary embolism; Evaluation of streptokinase and urokinase as thrombolytic agents.

  • Is Thrombolytic Therapy Effective for Pulmonary Embolism? Almoosa, Khalid // American Family Physician;3/15/2002, Vol. 65 Issue 6, p1097 

    Pulmonary embolism is a disorder that is associated with significant morbidity and mortality. Right-sided heart failure and recurrent pulmonary embolism are the main causes of death associated with pulmonary embolism in the first two weeks after the embolic event. Thrombolysis is a potentially...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics